{"id":"W4404310655","doi":"10.1056/nejmc2404555","title":"Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19","year":2024,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Virology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Monoclonal antibody; Medicine; Antibody; Immunology; Internal medicine; Outbreak; Infectious disease (medical specialty)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002699331,0.0005461617,0.0009496206,0.0004251389,0.0005530369,0.001036044,0.0009951048,0.003435316,0.00575774],"category_scores_gemma":[0.0113771,0.0002887163,0.0005314922,0.0002909209,0.0006315064,0.0007914564,0.000203405,0.005216274,0.001701408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009281757,"about_ca_system_score_gemma":0.0007641525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005874444,"about_ca_topic_score_gemma":0.002171928,"domain_scores_codex":[0.9988065,0.0004309569,0.0001553741,0.0001528391,0.000337527,0.0001168242],"domain_scores_gemma":[0.9958351,0.002428389,0.0004201519,0.00007989992,0.0009129741,0.0003234318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003305394,0.0001377656,0.001160346,0.001463091,0.0001621201,0.001369728,0.00005517063,0.0001518573,0.001993,0.001401166,0.9014578,0.0873426],"study_design_scores_gemma":[0.00254781,0.001497437,0.005252105,0.001512965,0.0006578054,0.003131929,0.0001158157,0.002004398,0.006189666,0.001733935,0.9752802,0.00007593619],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.01130599,0.08090359,0.001733451,0.4519705,0.4427225,0.0001971025,0.0005707698,0.0001836998,0.01041239],"genre_scores_gemma":[0.07179733,0.04900476,0.001522781,0.2876121,0.5593268,0.0001746539,0.0002942753,0.00009361325,0.03017366],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.00575774,"threshold_uncertainty_score":0.0192616,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06870392769362334,"score_gpt":0.4173853612704053,"score_spread":0.3486814335767819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}